IDENTIFYING AND TREATING AUTOIMMUNE NEUROLOGICAL DISORDERS
With
Associate Professor Sudarshini (Darshi) Ramanathan,
Neurologist & Head of Translational Neuroimmunology Group
Faculty of Medicine and Health
University of Sydney, Australia
RESEARCHER PROFILE
Filmed in Sydney, Australia | April 2026
Associate Professor Sudarshini Ramanathan is a neurologist and clinician scientist whose work focuses on autoimmune neurological disorders. Her research has helped identify new neurological syndromes due to antibody-mediated demyelination and encephalitis, and improve diagnostic tools and treatment guidelines for patients with autoimmune diseases affecting the brain, spinal cord, muscles and nerves.
Associate Professor Ramanathan’s research program aims to improve our understanding of underlying disease pathogenesis with a focus towards ‘precision medicine’ in neuroimmunology – both with diagnosis and therapeutics. Her research focuses on defining the clinical, radiological, and immunophenotypic profiles of specific pathogenic autoantibodies; understanding what triggers autoimmunity and disruption of immune tolerance; and the cellular and humoural mechanisms of action of autoantibodies and how this might be translated into refining novel therapeutic approaches.
Her work thus far has resulted in the enhanced recognition of novel treatable neurological conditions, important biological insights into the pathophysiology of these disorders, and the development of diagnostic criteria and therapeutic approaches to improve outcomes in vulnerable patients who otherwise risk chronic disability.
Associate Professor Ramanathan heads the Translational Neuroimmunology Group at the Faculty of Medicine and Health, University of Sydney; and also runs a neuroimmunology clinic at Concord Hospital. She supervises and mentors a research team of PhD and Masters candidates, postdoctoral fellows, and clinician researchers. Her research has been recognised by the Leonard Cox Award for Excellence in Neuroscience research and the NSW Premier’s Prize Award for Early Career Researchers (Biological Sciences) in 2022.
Source: Supplied
https://orcid.org/0000-0002-0294-9768
-
Visceral pain and the gut-brain axis
Professor Stuart Brierley is Director of the Visceral Pain Research Group, Director of the Hopwood Centre for Neurobiology, and Theme co-Leader of Lifelong Health at the South Australian Health and Medical Research Institute (SAHMRI).
Prof Brierley is an international expert on the ‘gut-brain axis’ and chronic visceral pain mechanisms. Current investigations are on a individual cell type called the enterochromaffin cell, and it helps signal pain and anxiety from the gastrointestinal tract to the brain.
-
Muscle Cell Communication and Repair
Dr. William Roman is a Group Leader at the Australian Regenerative Medicine Institute (ARMI) at Monash University. He obtained his PhD from Paris Descartes University and Freie University of Berlin, focusing on nuclear positioning during skeletal muscle development. Dr. Roman’s research journey has taken him across the globe, including postdoctoral work in Barcelona, tissue engineering in Lisbon, and a brief stint at Stanford University.
At ARMI, Dr. Roman leads innovative research on intercellular communication within muscle organs. His work involves growing human muscles on chips to understand how skeletal muscle cells interact with neurons and tendons. This research aims to develop better models for studying muscle diseases, drug screening, and even applications in cellular agriculture and biorobotics.
-
Cellular mechanisms of traumatic brain injury & concussion
Professor Melinda Fitzgerald is Deputy Vice Chancellor, Research at Curtin University, John Curtin Distinguished Professor and CEO of Connectivity Traumatic Brain Injury Australia.
She has published over 135 papers; recent highlights include Lancet Neurology, J Neuroscience, Nature Nano, ACS Nano, Biomaterials. Currently held grants/Projects total $10.1 million; CIA for $5.2 million of these; $18.5 million total research and equipment funding, $9.9 million as CIA; continuous category 1 grant funding as CIA since 2009.
